Insider Selling: Exagen (NASDAQ:XGN) CEO Sells $269,893.78 in Stock

Posted by Geri Gentry on Oct 22nd, 2026

Exagen Inc. (NASDAQ:XGN – Get Free Report) CEO John Aballi sold 34,294 shares of Exagen stock in a transaction dated Friday, October 16th. The shares were sold at an average price of $7.87, for a total value of $269,893.78. Following the sale, the chief executive officer owned 805,540 shares of the company’s stock, valued at approximately $6,339,599.80. This trade represents a 4.08% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Exagen Stock Performance

Shares of NASDAQ XGN opened at $7.88 on Thursday. Exagen Inc. has a 12 month low of $2.59 and a 12 month high of $12.23. The company has a debt-to-equity ratio of 1.96, a current ratio of 3.18 and a quick ratio of 3.18. The business has a 50-day moving average of $7.79 and a 200-day moving average of $5.48.

Exagen (NASDAQ:XGN – Get Free Report) last announced its earnings results on Tuesday, August 4th. The company reported ($0.13) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.19) by $0.06. Exagen had a negative net margin of 26.61% and a negative return on equity of 104.46%. The business had revenue of $19.94 million for the quarter, compared to the consensus estimate of $17.80 million. As a group, sell-side analysts expect that Exagen Inc. will post -0.69 EPS for the current fiscal year.

Institutional Investors Weigh In On Exagen

A number of institutional investors have recently made changes to their positions in the business. GSA Capital Partners LLP purchased a new position in Exagen in the 2nd quarter worth $998,000. Flputnam Investment Management Co. bought a new stake in Exagen in the second quarter worth $1,343,000. Man Group plc purchased a new stake in Exagen during the second quarter valued at about $778,000. FourWorld Capital Management LLC boosted its position in Exagen by 61.2% during the first quarter. FourWorld Capital Management LLC now owns 439,950 shares of the company’s stock valued at $1,320,000 after buying an additional 166,950 shares during the period. Finally, BlackRock Inc. bought a new position in shares of Exagen during the second quarter valued at about $663,000. Hedge funds and other institutional investors own 75.25% of the company’s stock.

Analyst Upgrades and Downgrades

A number of analysts have recently issued reports on XGN shares. B. Riley Financial began coverage on shares of Exagen in a report on Friday, September 11th. They set a “buy” rating and a $12.00 price objective for the company. Canaccord Genuity Group increased their target price on Exagen from $9.00 to $11.00 and gave the company a “buy” rating in a research note on Monday. BTIG Research raised their price target on Exagen from $8.00 to $9.00 and gave the company a “buy” rating in a research report on Wednesday, August 5th. Weiss Ratings restated a “sell (e+)” rating on shares of Exagen in a research report on Friday, August 7th. Finally, TD Cowen lifted their price target on Exagen from $10.00 to $11.00 and gave the stock a “buy” rating in a research note on Tuesday, October 13th. One investment analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $10.12.

View Our Latest Stock Analysis on XGN

About Exagen

(Get Free Report)

Exagen Inc (NASDAQ: XGN) is a diagnostic healthcare company focused on autoimmune diseases. The company develops and commercializes blood tests designed to help physicians diagnose, differentiate and monitor conditions such as systemic lupus erythematosus, rheumatoid arthritis and other connective tissue diseases.

Exagen’s principal product family is AVISE, a suite of proprietary autoimmune testing services that includes AVISE CTD, AVISE Lupus and monitoring tests. These assays combine multiple biomarkers and are intended to provide physicians with information that may support earlier or more informed clinical decisions, particularly in rheumatology.

Exagen operates a specialized laboratory testing business serving healthcare providers primarily in the United States.